WCMC-Q researchers make cancer breakthrough
Doha, January 17, 2012
Researchers at Weill Cornell Medical College in Qatar (WCMC-Q) have made a possible advancement in the way ovarian cancer is treated.
Using the latest techniques and taking a new approach involving studying a smaller sample and deeper analysis of the genetic abnormalities of the metastasized lesions, researchers found clear differences between the genetic expression of the primary ovarian cancer and the metastasized lesions, a statement said.
This indicates that when treating ovarian cancer with modern medication, consideration needs to be given to how these lesions respond and that may include tailoring the treatment based on combined biology of the primary ovarian cancer and metastatic lesions, it said.
Dr Jeremie Arash Rafii Tabrizi, assistant professor of genetic medicine in obstetrics and gynecology; and Dr Joel Malek, director of the genomics laboratory and instructor in genetic medicine; have been working closely with institutions in France, Singapore, Canada and the US to produce the report.
The study has been published in PLoS ONE, the peer-reviewed journal produced by the Public Library of Science.
Ovarian cancer is the sixth most common malignant cancer in women and the leading cause of death from gynecological cancer in the world.
The poor overall survival rate of 20 to 30 percent at five years is due to the large tumour burden with extensive metastatic lesions of the peritoneal cavity. In other words, it often goes undetected until it has spread to other parts of the abdomen becomes metastasized. This aggressive form of secondary cancer is often what causes death.
“Our findings are significant and important because most patients are diagnosed at the advanced stage of the disease. This means there are metastasized lesions present in the abdomen and by studying patients whose primary ovarian cancer is very similar; we have shown that the metastasized lesions, often the most dangerous part of the disease, are different. This means they may respond differently, possibly better, to a different cancer drug,” said Dr Tabrizi.
“Past research has focused on the primary cancer, often looking at the genomics of hundreds of tumors. Our approach is different because we decided to focus our research on the metastasis biology rather than only on the primary tumor,” he said.
The next step according to Dr Tabrizi is to produce a larger study to confirm these findings and also to study how different the metastatic lesions are within a single patient.
“This could open the door to new therapeutic approaches that tailors the treatment to the biology of the metastatic lesions,” he concluded. – TradeArabia News Service
More Health & Environment Stories
- The age of genomic medicine dawns, finally
- Over 300 exhibitors for Saudi healthcare event
- Mackeen unveils document management solution
- Seha opens new clinics in Abu Dhabi, Al Ain
- SARS virus claims one more victim in Saudi
- New support group comes to overeaters' rescue
- RAK Hospital launches urinary clinic for women
- NBAD backs Emiratis on Antarctica trip
- Cut sugar intake drastically urges WHO
- Al khaliji to fund Qatar recycling plant
- Qatar researcher in 360km breast cancer run
- New facilitator to open in DHCC
- Many countries lack capacity to prevent hearing loss
- QUIT NOW: Passive smoking hurts kids' arteries
- San Francisco to ban plastic water bottles
- GSK wins home toothpaste award for Sensodyne
- E-integration vital to GCC healthcare industry
- Fakih IVF unveils two new genetic tests
- 2 die from H1N1 in Oman
- Al Noor Hospitals targets domestic growth
- Medical panel on the way in Bahrain
- 40pc of UAE adults ‘have hypertension’
- Saudi diabetics urged to stay away from camels
- GCC readies plan to fight heart diseases
- Bahrain opens sickle cell hospital
- Hazardous waste focus for Oman summit
- Infectious viruses to be tracked by satellite in UAE
- Mafraq Hospital names new surgery chief
- Saudi health ministry seals BMJ partnership
- Need for medical simulation training highlighted